|
End-of-day quote
Dhaka S.E.
17/11/2026
|
5-day change | 1st Jan Change | ||
| 210.40 BDT | -4.23% |
|
-4.06% | +5.94% |
| 11-10 | Square Pharmaceuticals PLC. Reports Earnings Results for the First Quarter Ended September 30, 2026 | CI |
| 10-27 | Square Pharmaceuticals plc announces Annual dividend, payable on January 14, 2027 | CI |
| Market Cap | 187B 1.49B 1.36B 1.25B 1.13B 2.13B 139B 2.21B 15.09B 5.97B 75.27B 5.6B 5.48B 238B | P/E 2026 * |
7.11x | P/E 2027 * | 6.33x |
|---|---|---|---|---|---|
| Enterprise Value | 187B 1.49B 1.36B 1.25B 1.13B 2.13B 139B 2.21B 15.09B 5.97B 75.27B 5.6B 5.48B 238B | EV / Sales 2026 * |
2.18x | EV / Sales 2027 * | 1.97x |
| Free-Float |
55.9% | Yield 2026 * |
6.65% | Yield 2027 * | 8.32% |
| 1 day | -4.23% | ||
| 1 week | -4.06% | ||
| Current month | -3.71% | ||
| 1 month | -4.28% | ||
| 3 months | -3.84% | ||
| 6 months | +1.11% | ||
| Current year | +5.94% |
| 1 week | 209.2 | 220.1 | |
| 1 month | 209.2 | 220.4 | |
| Current year | 198.1 | 236 | |
| 1 year | 198 | 236 | |
| 3 years | 197.2 | 249.8 | |
| 5 years | 197.2 | 249.8 | |
| 10 years | 149.05 | 278.67 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/01/1995 | |
| Director of Finance/CFO | - | - | |
| Compliance Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 01/01/2012 | |
| Director/Board Member | - | 01/01/1980 | |
Ratna Patra
BRD | Director/Board Member | - | 01/01/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.23% | -4.06% | +3.54% | -0.71% | 1.56B | ||
| -1.13% | -1.17% | +38.55% | +139.23% | 1,275B | ||
| -1.36% | -0.74% | +39.64% | +86.06% | 680B | ||
| -0.59% | -0.36% | +25.14% | +111.73% | 521B | ||
| -0.76% | +1.10% | +41.43% | +70.96% | 389B | ||
| -0.75% | -3.16% | +54.39% | +40.90% | 356B | ||
| -1.83% | -0.89% | +26.00% | +58.48% | 305B | ||
| -1.65% | -0.59% | +1.55% | +34.52% | 287B | ||
| -0.95% | -1.57% | +34.01% | +72.55% | 250B | ||
| +1.60% | -0.36% | +37.21% | +125.66% | 208B | ||
| Average | -1.16% | -0.74% | +30.15% | +73.94% | 427B | |
| Weighted average by Cap. | -0.98% | -0.55% | +34.95% | +95.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 85.4B 684M 621M 573M 517M 976M 63.87B 1.01B 6.91B 2.73B 34.46B 2.56B 2.51B 109B | 94.79B 759M 689M 636M 574M 1.08B 70.89B 1.13B 7.67B 3.03B 38.25B 2.85B 2.79B 121B |
| Net income | 26.34B 211M 191M 177M 160M 301M 19.7B 313M 2.13B 843M 10.63B 791M 775M 33.59B | 29.57B 237M 215M 198M 179M 338M 22.12B 351M 2.39B 946M 11.93B 888M 869M 37.7B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/11/26 | BDT 210.40 | -4.23% | 1,645,144 |
| 15/11/26 | BDT 219.70 | +0.41% | 921,119 |
| 12/11/26 | BDT 218.80 | +0.09% | 559,507 |
| 11/11/26 | BDT 218.60 | -0.32% | 457,766 |
| 10/11/26 | BDT 219.30 | +0.09% | 419,941 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- SQURPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
















